Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease pleural effusion disorder
Phenotype C0149925|small cell lung cancer
Sentences 10
PubMedID- 20819493 Objective: to compare the therapeutic effects of pleural perfusion of ndp and cddp in non-small cell lung cancer (nsclc) patients with malignant pleural effusion, their quality of life and toxic side effects.
PubMedID- 23523589 The diagnostic value of apolipoprotein e in malignant pleural effusion associated with non-small cell lung cancer.
PubMedID- 26323029 Purpose to determine the frequency and investigate possible mechanisms and prognostic relevance of minimal (<10-mm thickness) pleural effusion in patients with small cell lung cancer (sclc).
PubMedID- 20207133 Purpose: to investigate the feasibility, pharmacokinetics, efficacy and toxicity of intrapleural paclitaxel liposome injection in non-small cell lung cancer (nsclc) patients with malignant pleural effusions.
PubMedID- 23925664 Vascular endothelial growth factor (vegf) is involved in non-small cell lung cancer (nsclc) with malignant pleural effusion (mpe), but little is known regarding the efficacy of bevacizumab (bev) with carboplatin-paclitaxel (cp) for nsclc with mpe.
PubMedID- 24758329 Prognostic value of secreted phosphoprotein-1 in pleural effusion associated with non-small cell lung cancer.
PubMedID- 26005243 The patients studied here are enrolled in a phase i clinical trial of hpph-mediated pdt for the treatment of non-small cell lung cancer with pleural effusion.
PubMedID- 21625182 Predictive value of f-18 fdg pet/ct for malignant pleural effusion in non-small cell lung cancer patients.
PubMedID- 23898708 However, this condition is sometimes discovered, with or without a small amount of pleural effusion, at thoracotomy in patients with resectable non-small cell lung cancer.
PubMedID- 25999646 Patients in this study are enrolled in a phase i clinical trial of hpph-mediated pdt for the treatment of non-small cell lung cancer with pleural effusion.

Page: 1